Cancer Pain Management and Bone Metastases: An Update for the Clinician

被引:34
作者
Schneider, Guido [1 ,2 ,3 ]
Voltz, Raymond [1 ,2 ,3 ]
Gaertner, Jan [1 ,2 ,3 ]
机构
[1] Univ Hosp Cologne, Dept Palliat Care, D-50924 Cologne, Germany
[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany
[3] Cologne Clin Trials Ctr, Cologne, Germany
关键词
Breast cancer; Palliative care; Palliative medicine; Bone metastases; Cancer pain; Opioids; Guidelines; QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EVIDENCE-BASED-RECOMMENDATIONS; NEUROPATHIC PAIN; OPIOID ROTATION; ORAL METHADONE; DOUBLE-BLIND; CARE; RELEASE; MODERATE;
D O I
10.1159/000338579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer patients with bone metastases often suffer from cancer pain. In general, cancer pain treatment is far from being optimal for many patients. To date, morphine remains the gold standard as first-line therapy, but other pure mu agonists such as hydromorphone, fentanyl, or oxycodone can be considered. Transdermal opioids are an important option if the oral route is impossible. Due to its complex pharmacology, methadone should be restricted to patients with difficult pain syndromes. The availability of a fixed combination of oxycodone and naloxone is a promising development for the reduction of opioid induced constipation. Especially bone metastases often result in breakthrough pain episodes. Thus, the provision of an on-demand opioid (e.g., immediate-release morphine or rapid-onset fentanyl) in addition to the baseline (regular) opioid therapy (e.g., sustained-release morphine tablets) is mandatory. Recently, rapid onset fentanyls (buccal or nasal) have been strongly recommended for breakthrough cancer pain due to their fast onset and their shorter duration of action. If available, metamizole is an alternative non-steroid-anti-inflammatory-drug. The indication for bisphosphonates should always be checked early in the disease. In advanced cancer stages, glucocorticoids are an important treatment option. If bone metastases lead to neuropathic pain, coanalgetics (e.g., pregabalin) should be initiated. In localized bone pain, radiotherapy is the gold standard for pain reduction in addition to pharmacologic pain management. In diffuse bone pain radionuclids (such as samarium) can be beneficial. Invasive measures (e.g., neuroaxial blockage) are rarely necessary but are an important option if patients with cancer pain syndromes are refractory to pharmacologic management and radiotherapy as described above. Clinical guidelines agree that cancer pain management in incurable cancer is best provided as part of a multiprofessional palliative care approach and all other domains of suffering (psychosocial, spiritual, and existential) need to be carefully addressed ('total pain').
引用
收藏
页码:113 / 120
页数:8
相关论文
共 61 条
[11]   Integrative and Behavioral Approaches to the Treatment of Cancer-Related Neuropathic Pain [J].
Cassileth, Barrie R. ;
Keefe, Francis J. .
ONCOLOGIST, 2010, 15 :19-23
[12]   Cycloxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation [J].
Chen, Y-F ;
Jobanputra, P. ;
Barton, P. ;
Bryan, S. ;
Fry-Smith, A. ;
Harris, G. ;
Taylor, R. S. .
HEALTH TECHNOLOGY ASSESSMENT, 2008, 12 (11) :1-+
[13]   Palliative radiotherapy trials for bone metastases: A systematic review [J].
Chow, Edward ;
Harris, Kristin ;
Fan, Grace ;
Tsao, May ;
Sze, Wai M. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1423-1436
[14]   Control of pain in adults with cancer: summary of SIGN guidelines [J].
Cormie, P. J. ;
Nairn, M. ;
Welsh, J. .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 :1106-1109
[15]   Effect of bisphosphonates on pain and quality of life in patients with bone metastases [J].
Costa, Luis ;
Major, Pierre P. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (03) :163-174
[16]   Prevalence of undertreatment in cancer pain. A review of published literature [J].
Deandrea, S. ;
Montanari, M. ;
Moja, L. ;
Apolone, G. .
ANNALS OF ONCOLOGY, 2008, 19 (12) :1985-1991
[17]  
Dunlop William, 2012, J Med Econ, V15, P564, DOI 10.3111/13696998.2012.665279
[18]   Evidence-based standards for cancer pain management [J].
Dy, Sydney M. ;
Asch, Steven M. ;
Naeim, Arash ;
Sanati, Homayoon ;
Walling, Anne ;
Lorenz, Karl A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (23) :3879-3885
[19]  
Elsner F, 2005, J Palliat Med, V8, P743, DOI 10.1089/jpm.2005.8.743
[20]   Palliative Cancer Care a Decade Later: Accomplishments, the Need, Next Steps-From the American Society of Clinical Oncology [J].
Ferris, Frank D. ;
Bruera, Eduardo ;
Cherny, Nathan ;
Cummings, Charmaine ;
Currow, David ;
Dudgeon, Deborah ;
JanJan, Nora ;
Strasser, Florian ;
von Gunten, Charles F. ;
Von Roenn, Jamie H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :3052-3058